Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-01
2005-02-01
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S271700
Reexamination Certificate
active
06849647
ABSTRACT:
The present invention provides to a novel compound having an ACAT inhibiting activity.The present invention relates to compounds represented by formula (I)wherein represents an optionally substituted divalent residue such as benzene, pyridine, cyclohexane or naphthalene, or a group,Het represents a 5- to 8-membered, substituted or unsubstituted heterocyclic group containing at least one heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, such as a monocyclic group, a polycyclic group or a group of a fused ring,X represents —NH—, an oxygen atom or a sulfur atom,Y represents —NR4—, an oxygen atom, a sulfur atom, a sulfoxide or a sulfone,Z represents a single bond or —NR5—,R4represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group,R5represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, andn is integer of from 1 to 15,or salts or solvates thereof, and a pharmaceutical composition containing at one of these compounds.
REFERENCES:
patent: 5290801 (1994-03-01), Higley et al.
patent: 5358946 (1994-10-01), Wilde
patent: 0807627 (1997-11-01), None
patent: 04-139172 (1992-05-01), None
Mahmoud et al., Gazz. Chim. Ital. (1982), 112(1-2), pp. 55-56 and CA 97:72288, 1982.*
Mahmoud et al., Eur. J. Med. Chem.—Chim. Ther. (1981) 16(4), pp. 383-384 and CA 95:169076 1981.*
Abdel Rahman et al. J. Indian Chem. Soc. (1981), 58(2), pp. 171-173 and CA 95:42967, 1981.*
Brandstrom et al., “Structure activity relationships of substituted benzimidazoles,”Scand. J. Gastroenterol., 20(Suppl. 108) pp. 15-22 (1985).
Lindberg et al., “The Mechanism of Action of the Gastric Acid Secretion Inhibitor Omeprazole,”Journal of Medicinal Chemistry, vol. 29, No. 8, pp. 1327-1329 (1986).
Richard G. Wilde, et al., “ACYL CoA: Cholesterol Acyltransferase (ACAT) Inhibitors: Ureas Bearing Heterocyclic Groups Bioisosteric For An Imidazole,” Bioorganic & Med. Chem. Letters, vol. 5 No. 2 (1995) pp. 167-172.
Richard G. Wilde, et al., “ACYL CoA: Cholesterol Acyltransferase (ACAT) Inhibitors: Ureas Bearing Two Heterocyclic Head Groups,” Bioorganic & Med. Chem. Letters, vol. 5, No. 2, (1995) pp. 173-176.
K. Matsuda, “ACAT Inhibitors as Antiatherosclerotic Agents: Compounds and Mechanisms,” vol. 14, No. 4, 1994, pp. 271-305.
R. Bellemin et al., “New indole derivatives as ACAT inhibitors: synthesis and structure- activity relationships,” Eur. J. Med. Chem., vol. 31, 1996, pp. 123-132.
Edano Toshiyuki
Hirata Mitsuteru
Kawamine Katsumi
Kitamura Takahiro
Miura Toru
Alexander John B.
Corless Peter F.
Edwards & Angell LLP
Kowa Company Ltd.
Stockton Laura L.
LandOfFree
Amide compounds and medications containing the same... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amide compounds and medications containing the same..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amide compounds and medications containing the same... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3453306